Title: Jens Wolfel: Innovator in Recombinant Glycoprotein Production
Introduction
Jens Wolfel is a notable inventor based in Germany, recognized for his contributions to the field of biotechnology. His work primarily focuses on the development of cell lines for the production of recombinant glycoproteins. Despite having no patents to his name, his research has significant implications for the production of sialylated glycoproteins.
Latest Patents
Jens Wolfel's notable invention is titled "O-Glycan Sialylated Recombinant Glycoproteins And Cell Lines For Producing The Same." This invention relates to genetically modified cell lines that overexpress a ß-galactoside a-2,3-sialyltransferase 1 (ST3Gal1), specifically human ST3Gal1. These cell lines are designed for the production of recombinant glycoproteins that possess highly or fully sialylated O-linked GalNAc glycans. The invention also encompasses methods for expressing these glycoproteins, increasing their sialylation, and reducing the micro-heterogeneity of GalNAc O-glycans.
Career Highlights
Jens Wolfel is currently employed at Cevec Pharmaceuticals GmbH, where he continues to advance his research in glycoprotein production. His work is pivotal in enhancing the efficiency and quality of recombinant glycoproteins, which are essential in various therapeutic applications.
Collaborations
Jens collaborates with esteemed colleagues such as Silke Wissing and Nicole Faust, contributing to a dynamic research environment that fosters innovation in biotechnology.
Conclusion
Jens Wolfel's work in the field of recombinant glycoproteins showcases his commitment to advancing biotechnological applications. His innovative approaches have the potential to significantly impact the production of therapeutic proteins.